VXRT - Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

• A services agreement that Vaxart recently brokered with contract research organization hVIVO Services Ltd. "may be integral to its Covid vaccine candidate program," according to an SEC filing .
• That agreement , signed in late June, has hVIVO conducting a characterization study of the company's COVID-19 pill vaccine candidate. The purpose is to establish a dose of the Omicron challenge virus that will cause a safe and reliable infection in healthy volunteers.
• The trial is expected to have five cohorts and 36 participants.
• If the study is successful, Vaxart ( NASDAQ: VXRT ) will have hVIVO conduct a challenge study against the Omicron variant.
• Details also call for hVIVO to contract with a second client for another characterization study and a separate a separate challenge study.
• A deep dive into Vaxart ( VXRT ) was provided recently by Seeking Alpha contributor Bret Jensen.

For further details see: